Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | CSF1R | P07333 | 18/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.52 |
| ▸ | KIT | P10721 | 6/20 | 0.52 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23900628 | 0.85 | CSF1R (0.62) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL29736768 | 0.85 | KDR (0.52) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL574068 | 0.85 | KDR (0.52) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL14447156 | 0.84 | FYN (0.58) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL2415726 | 0.81 | KDR (0.52) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL24783964 | 0.81 | MAPT (0.48) | KDRCSF1RFLT3MET | |
| SCHEMBL16060927 | 0.80 | CSF1R (0.56) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL2416158 | 0.80 | CSF1R (0.54) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL30086949 | 0.80 | CSF1R (0.54) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL16059753 | 0.80 | CSF1R (0.61) | KDRCSF1RPDGFRAKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 555/4885CSF1R 1214/4885PDGFRA 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.